New developments in targeting the B cell receptor pathway
Orlando bound for ASH!
What is old is new again…
I have that distinct feeling of deja vu with the ASH asbtract drop yesterday on several fronts. It’s quite a few years now since we wrote about the runners and riders in the BTK/PI3K race to market in CLL and by weird coincidence a topic I was covering by interview yesterday on the RAS pathway came up in one of the first ASH asbtracts I was reading, which was rather spooky. Clearly Halloween came slightly late to Florida this year!
So how do all these disparate topics hang together and why are we excited about a small cap biotech company that is largely under many people’s radar?
They have some unexpected unifying threads…
To learn more from our oncology coverage and get a heads up on insights from the first of first ASH19 Previews, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers
